Tariffs in SCOTUS; Pfizer v. Novo, Metsera
Échec de l'ajout au panier.
Veuillez réessayer plus tard
Échec de l'ajout à la liste d'envies.
Veuillez réessayer plus tard
Échec de la suppression de la liste d’envies.
Veuillez réessayer plus tard
Échec du suivi du balado
Ne plus suivre le balado a échoué
Tariffs in SCOTUS; Pfizer v. Novo, Metsera
-
Narrateur(s):
-
Auteur(s):
À propos de cet audio
Key takeaways from Supreme Court arguments on Nov. 5 over the legality of the Trump administration's reciprocal and fentanyl-linked tariffs led Bloomberg Intelligence's Votes and Verdicts podcast this week. Holly Froum examined that while BI litigation and policy analysts discuss other important catalysts. Holly and Jen Rie analyzed litigation concerning a bidding war between Pfizer and Novo Nordisk for Metsera, a clinical-stage biotech company that makes anti-obesity drugs. Holly and Jen also discussed legal issues pertaining to Kimberly-Clark's $48 billion acquisition of Kenvue. Nathan Dean offered his views on paths being discussed to end the government shutdown.
See omnystudio.com/listener for privacy information.
Pas encore de commentaire